Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons Y. van Sleen

Publicaties

Clonal hematopoiesis and UBA1 mutations in individuals with biopsy-proven giant cell arteritis and population-based controls

Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica

A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452

Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?

Cytokine producing B-cells and their capability to polarize macrophages in giant cell arteritis

Disease stratification in GCA and PMR: state of the art and future perspectives

Effect of DMARDs on the immunogenicity of vaccines

Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients

Frailty is related to serum inflammageing markers: results from the VITAL study

Humoral SARS-CoV-2 Vaccine Responses in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica: Decay After Primary Vaccination and Effects of the Booster

Lees meer

Pers/media

How Does COVID-19 Booster Affect Patients With GCA and Low Primary Vaccine Response?

Biomarkers may improve giant cell arteritis diagnosis

Vasculitis Foundation: international research insights